Stock PROC PROCAPS GROUP S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Procaps Group S.A.

Equities

PROC

LU2376511205

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-01 pm EDT 		5-day change 1st Jan Change
2.775 USD +5.92% Intraday chart for Procaps Group S.A. +0.91% -31.82%
May. 01 Procaps Group S.A. Provides Earnings Guidance for the Year Ended December 31, 2023 CI
Mar. 04 Procaps Group S.A. Announces Formation of Strategic Committee to Explore Value Creation Alternatives CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Capitalization 1 260 1,100 592.3 313.1 313.1 -
Enterprise Value (EV) 1 260 1,281 835.3 313.1 313.1 313.1
P/E ratio - -9.47 x 12.5 x 5.78 x 7.3 x -
Yield - - - - - -
Capitalization / Revenue 0.78 x 2.68 x 1.45 x 0.74 x 0.68 x 0.6 x
EV / Revenue 0.78 x 2.68 x 1.45 x 0.74 x 0.68 x 0.6 x
EV / EBITDA - 11 x 8.45 x 3.24 x 3.21 x -
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book - - -263 x 5.9 x 3.23 x -
Nbr of stocks (in thousands) 25,000 112,824 112,824 112,824 112,824 -
Reference price 2 10.40 9.750 5.250 2.775 2.775 2.775
Announcement Date 6/21/21 4/30/22 5/12/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net sales 1 331.5 409.7 409.9 424.2 460.1 518.6
EBITDA 1 - 99.7 70.13 96.65 97.5 -
EBIT 1 - 84.6 40.09 77.1 76.8 -
Operating Margin - 20.65% 9.78% 18.18% 16.69% -
Earnings before Tax (EBT) 1 - - 52.71 76 61 -
Net income 1 -10.45 -100.9 42.54 54.1 43 48.1
Net margin -3.15% -24.62% 10.38% 12.75% 9.35% 9.27%
EPS 2 - -1.030 0.4200 0.4800 0.3800 -
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 6/21/21 4/30/22 5/12/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4
Net sales 1 126.5 85.63 112.4 110.4 101.5 84.16 110.1 118.4 110.6
EBITDA 1 42.1 4.679 27.5 22.9 10.53 9.4 17.84 22 30
EBIT 1 36.28 2.409 18.12 17.35 2.212 3.273 15.09 13.18 25.5
Operating Margin 28.68% 2.81% 16.12% 15.71% 2.18% 3.89% 13.71% 11.13% 23.06%
Earnings before Tax (EBT) - - - - - - - - -
Net income - - - - - - - - -
Net margin - - - - - - - - -
EPS - - - - - - - - -
Dividend per Share - - - - - - - - -
Announcement Date 4/30/22 6/15/22 8/30/22 11/14/22 5/12/23 6/6/23 9/5/23 12/26/23 -
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net Debt - 181 243 - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - 1.818 x 3.464 x - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) - - - 184% 57.4% -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share 2 - - -0.0200 0.4700 0.8600 -
Cash Flow per Share - - - - - -
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 6/21/21 4/30/22 5/12/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Procaps Group S.A.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.775 USD
Average target price
4.75 USD
Spread / Average Target
+71.17%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
PROCAPS GROUP S.A. Stock Procaps Group S.A.
-31.82% 313M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+33.25% 699B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.43% 571B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.55% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.16% 326B
ABBVIE INC. Stock AbbVie Inc.
+4.36% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.75% 236B
NOVARTIS AG Stock Novartis AG
+4.93% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-10.18% 194B
AMGEN INC. Stock Amgen Inc.
-3.69% 149B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PROC Stock
  4. Financials Procaps Group S.A.